Pfizer vs. CVS Caremark: Which Stock's Dividend Dominates?

Dividend stocks outperform non-dividend-paying stocks over the long run. It happens in good markets and bad, and the benefit of dividends can be quite striking -- dividend payments have made up about 40% of the market's average annual return from 1936 to the present day.

But few of us can invest in every single dividend-paying stock on the market, and even if we could, we're likely to find better gains by being selective. Today, two leading health-care companies will square off in a head-to-head battle to determine which offers a better dividend for your portfolio.

Tale of the tape
Founded in 1849, Pfizer (NYSE: PFE  ) is one of the world's largest pharmaceutical companies. It has developed many blockbuster drugs over the years, and has played a critical role in moving the industry toward a more promotional mind-set in recent decades. Headquartered in New York, Pfizer has augmented its global health care portfolio through various major acquisitions over the past decade: Warner–Lambert in 2000; Pharmacia in 2003; and Wyeth in 2009. Earlier this year, Pfizer spun off Zoetis, previously known as Pfizer Animal Health, to focus on the development of drugs and vaccines for humans.

CVS Caremark (NYSE: CVS  ) , formed by the merger of CVS Pharmacy and Caremark Rx in 2007, is among the Top 20 Fortune 500 companies in the U.S. Headquartered in Woonsocket, Rhode Island, CVS is the largest U.S. pharmacy in terms of total prescription revenue, and has more 7,500 CVS/pharmacy stores, 31 specialty pharmacies, and around 650 MinuteClinic locations in 27 states. CVS is also expanding internationally, with the recent acquisition of retail drugstore chain Onofre in Brazil.

Statistic

Pfizer

CVS Caremark

Market cap

$200.3 billion

$73.7 billion

P/E ratio

19.6

17.8

Trailing 12-month profit margin

46.6%

3.4%

TTM free cash flow margin*

26.6%

2.6%

Five-year total return 

30.3%

60%

Source: Morningstar and YCharts.
*Free cash flow margin is free cash flow divided by revenue for the trailing 12 months.

Round one: endurance (dividend-paying streak)
Pfizer is one of long-term investors' favorite dividend stocks, as it's paid uninterrupted dividends for a continuous period of more than 30 years since initiating payment in 1982. CVS misses by a narrow margin of just three years, but it has also made regular payments to shareholders since 1985.

Winner: Pfizer, 1-0.

Round two: stability (dividend-raising streak)
Although Pfizer has paid regular dividends without reduction since 1982, it was forced to cut payouts during the financial crisis, and only resumed its trend of increasing payouts in 2010. By contrast, CVS' dividend payout has soared every year since 2008, with some hefty jumps seen in payments over the past couple of years.

Winner: CVS, 1-1.

Round three: power (dividend yield)
Some dividends are enticing, but others are merely tokens that barely affect an investor's decision. Have our two companies sustained strong yields over time? Let's take a look:

PFE Dividend Yield (TTM) Chart

PFE Dividend Yield (TTM) data by YCharts

Winner: Pfizer, 2-1.

Round four: strength (recent dividend growth)
A stock's yield can stay high without much effort if its share price doesn't budge, so let's look at the growth in payouts over the past five years.

PFE Dividend Chart

PFE Dividend data by YCharts

Winner: CVS, 2-2.

Round five: flexibility (free cash flow payout ratio)
A company that pays out too much of its free cash flow in dividends could be at risk of a cutback, particularly if business weakens. We want to see sustainable payouts, so lower is better:

PFE Cash Dividend Payout Ratio TTM Chart

PFE Cash Dividend Payout Ratio TTM data by YCharts

Winner: CVS, 3-2.

Bonus round: opportunities and threats
CVS Caremark may have won the best-of-five on the basis of its history, but investors should never base their decisions on past performance alone. Tomorrow might bring a far different business environment, so it's important to also examine each company's potential, whether it happens to be nearly boundless or constrained too tightly for growth.

Pfizer opportunities

CVS Caremark opportunities

Pfizer threats

CVS Caremark threats

One dividend to rule them all
In this writer's humble opinion, it seems that CVS Caremark has a better shot at long-term outperformance, thanks to its ability to augment its widespread geographical reach in the United States with new technologies, as well as its aggressive expansion plan for the next few years. By contrast, Pfizer faces fierce competition from generic drugs, but its proven competencies could result in many blockbuster treatments. You might disagree, and if so, you're encouraged to share your viewpoint in the comments below. No dividend is completely perfect, but some are bound to produce better results than others. Keep your eyes open -- you never know where you might find the next great dividend stock!

A portfolio full of dividend dynamos
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2690544, ~/Articles/ArticleHandler.aspx, 9/30/2014 4:36:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement